← Back to Investors

Novartis Venture Fund

Novartis Venture Fund is the corporate venture capital arm of Novartis, one of the world's largest pharmaceutical companies. They invest in innovative biotech and healthcare technology companies, with particular focus on areas aligned with Novartis's therapeutic interests and strategic priorities.

Location
Basel, Switzerland
Founded
1996
AUM
$800M+
Investment Range
$5M - $30M
Focus
cvc
Fund Stages
seed, series-a, series-b, series-c

Investment Thesis

Novartis Venture Fund invests in breakthrough therapeutics and healthcare technologies that can transform patient care. They provide capital alongside strategic partnership opportunities with Novartis's research and commercial organizations, focusing on innovative science with clinical and commercial potential.

Team

Partners / Managing Directors (Health & Bio Focus)

  • Birgit Tauber, PhD - Managing Director
  • Anja König, PhD - Partner

Other Key Team Members

  • Investment team with deep pharma R&D backgrounds

Focus Areas

  • Therapeutics (oncology, immunology, ophthalmology, CNS)
  • Gene therapy and cell therapy
  • Precision medicine
  • Digital therapeutics
  • Healthcare technology
  • Drug discovery platforms

Notable Exits

  • Intellia Therapeutics - IPO (gene editing)
  • CRISPR Therapeutics - Early investor (gene editing)
  • Multiple strategic acquisitions by Novartis and others
  • Strong track record in novel therapeutic modalities

Sources